基于肾纤维化机制的药物临床研究进展  

Advances in clinical research of drug treatment based on renal fibrosis mechanism

作　　者：罗丛伟 何晓洋[1] 彭芬芬[1] 王育娴 陈毅华[1] 龙海波[1] Luo Congwei;He Xiaoyang;Peng Fenfen;Wang Yuxian;Chen Yihua;Long Haibo(Zhujiang Hospital,Southern Medical University,Guangzhou 510280,Guangdong Province,China)

机构地区：[1]南方医科大学珠江医院,510280

出　　处：《中华肾病研究电子杂志》2020年第2期78-81,共4页Chinese Journal of Kidney Disease Investigation（Electronic Edition）

基　　金：国家自然科学基金(81673792、81704134、81873346、U1801288、81900607);广东省科技计划项目(2017A020215158)

摘　　要：肾纤维化是所有进展期慢性肾脏病的共有病理特征,预示肾损伤反应进入了以组织结构重塑和器官功能丧失为标志的共同终末通路。目前,临床上尚缺乏针对肾纤维化有效的治疗药物,导致大量肾纤维化患者不可避免地发展为终末期肾病。基于肾纤维化分子机制的研究进展,近年来多种具有潜在抗纤维化作用的药物已经进入了临床试验阶段。本文对部分受到密切关注的试验药物进行综述,以期对后续临床研究的开展带来帮助。Renal fibrosis is a common pathological feature of all advanced chronic kidney diseases,indicating that the renal injury has stepped into a common terminal pathway marked by remodeling of renal tissue structure and loss of renal function.At present,there is still a lack of effective therapeutic drugs for clinical treatment of renal fibrosis,and a large number of patients with renal fibrosis inevitably enter end-stage renal disease.Based on the progress of the molecular mechanism of renal fibrosis,a number of potential antifibrotic drugs have come into clinical trials in recent years.This review focused on some of the experimental drugs that have received intense attention,aiming to provide help for follow-up clinical researches.

关 键 词：肾纤维化 治疗药物 临床试验 

分 类 号：R692[医药卫生—泌尿科学]